Cargando…

Genomic and Proteomic Biomarker Discovery in Neurological Disease

Technology for high-throughout scanning of the human genome and its encoded proteins have rapidly developed to allow systematic analyses of human disease. Application of these technologies is becoming an increasingly effective approach for identifying the biological basis of genetically complex neur...

Descripción completa

Detalles Bibliográficos
Autores principales: Robeson, RiLee H., Siegel, Andrew M., Dunckley, Travis
Formato: Texto
Lenguaje:English
Publicado: Libertas Academica 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2688365/
https://www.ncbi.nlm.nih.gov/pubmed/19578496
_version_ 1782167699870187520
author Robeson, RiLee H.
Siegel, Andrew M.
Dunckley, Travis
author_facet Robeson, RiLee H.
Siegel, Andrew M.
Dunckley, Travis
author_sort Robeson, RiLee H.
collection PubMed
description Technology for high-throughout scanning of the human genome and its encoded proteins have rapidly developed to allow systematic analyses of human disease. Application of these technologies is becoming an increasingly effective approach for identifying the biological basis of genetically complex neurological diseases. This review will highlight significant findings resulting from the use of a multitude of genomic and proteomic technologies toward biomarker discovery in neurological disorders. Though substantial discoveries have been made, there is clearly significant promise and potential remaining to be fully realized through increasing use of and further development of -omic technologies.
format Text
id pubmed-2688365
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-26883652009-07-01 Genomic and Proteomic Biomarker Discovery in Neurological Disease Robeson, RiLee H. Siegel, Andrew M. Dunckley, Travis Biomark Insights Original Research Technology for high-throughout scanning of the human genome and its encoded proteins have rapidly developed to allow systematic analyses of human disease. Application of these technologies is becoming an increasingly effective approach for identifying the biological basis of genetically complex neurological diseases. This review will highlight significant findings resulting from the use of a multitude of genomic and proteomic technologies toward biomarker discovery in neurological disorders. Though substantial discoveries have been made, there is clearly significant promise and potential remaining to be fully realized through increasing use of and further development of -omic technologies. Libertas Academica 2008-02-09 /pmc/articles/PMC2688365/ /pubmed/19578496 Text en © 2008 by the authors http://creativecommons.org/licenses/by/3.0 This article is published under the Creative Commons Attribution By licence. For further information go to: http://creativecommons.org/licenses/by/3.0. (http://creativecommons.org/licenses/by/3.0)
spellingShingle Original Research
Robeson, RiLee H.
Siegel, Andrew M.
Dunckley, Travis
Genomic and Proteomic Biomarker Discovery in Neurological Disease
title Genomic and Proteomic Biomarker Discovery in Neurological Disease
title_full Genomic and Proteomic Biomarker Discovery in Neurological Disease
title_fullStr Genomic and Proteomic Biomarker Discovery in Neurological Disease
title_full_unstemmed Genomic and Proteomic Biomarker Discovery in Neurological Disease
title_short Genomic and Proteomic Biomarker Discovery in Neurological Disease
title_sort genomic and proteomic biomarker discovery in neurological disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2688365/
https://www.ncbi.nlm.nih.gov/pubmed/19578496
work_keys_str_mv AT robesonrileeh genomicandproteomicbiomarkerdiscoveryinneurologicaldisease
AT siegelandrewm genomicandproteomicbiomarkerdiscoveryinneurologicaldisease
AT dunckleytravis genomicandproteomicbiomarkerdiscoveryinneurologicaldisease